Bridgeway Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Bridgeway Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-51,500	Closed	-$111K	–	1311
2024 Q3	$111K	Hold	51,500	–	–	﹤0.01%	1152
2024 Q2	$266K	Hold	51,500	–	–	0.01%	992
2024 Q1	$276K	Buy	51,500 +12,000	+30%	+$83K	0.01%	1054
2023 Q4	$308K	Hold	39,500	–	–	0.01%	1059
2023 Q3	$156K	Hold	39,500	–	–	﹤0.01%	1141
2023 Q2	$124K	Sell	39,500 -10,000	-20%	-$32.1K	﹤0.01%	1223
2023 Q1	$132K	Buy	+49,500	New	+$192K	﹤0.01%	1181
2022 Q3	–	Sell	-9,500	Closed	-$91K	–	1460
2022 Q2	$91K	Sell	9,500 -7,500	-44%	-$70.2K	﹤0.01%	1238
2022 Q1	$202K	Hold	17,000	–	–	﹤0.01%	1170
2021 Q4	$554K	Buy	+17,000	New	+$688K	0.01%	953
2020 Q1	–	Sell	-3,330	Closed	-$230K	–	1368
2019 Q4	$230K	Hold	3,330	–	–	﹤0.01%	1177
2019 Q3	$346K	Hold	3,330	–	–	﹤0.01%	1063
2019 Q2	$308K	Sell	3,330 -4,000	-55%	-$279K	﹤0.01%	1090
2019 Q1	$670K	Buy	7,330 +740	+11%	+$51.5K	0.01%	911
2018 Q4	$367K	Sell	6,590 -2,000	-23%	-$152K	﹤0.01%	1086
2018 Q3	$1.02M	Hold	8,590	–	–	0.01%	870
2018 Q2	$877K	Sell	8,590 -1,380	-14%	-$171K	0.01%	924
2018 Q1	$1.29M	Buy	+9,970	New	+$1.09M	0.01%	747

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Bridgeway Capital Management's SYRS Position: Q4 2024 in Review

Bridgeway Capital Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 51,500 shares — an estimated $111K sold.

Bridgeway Capital Management first reported a position in SYRS in Q1 2018 and held it in 18 quarters. The position peaked at $1.29M in Q1 2018. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

Bridgeway Capital Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Bridgeway Capital Management sold 51,500 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $111K.
Bridgeway Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 18 quarters.
Bridgeway Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.29M in Q1 2018.
44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Bridgeway Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.